Please login (Members) to view content or
(Nonmembers) this article.
No votes yet
Clinical Challenges

Intraperitoneal Chemotherapy for Ovarian Cancer

Paula Anastasia
ONF 2012, 39(4), 346-349 DOI: 10.1188/12.ONF.346-349

Ovarian cancer remains an uncommon cancer compared to other female malignancies, such as breast, lung, and colon cancer. However, ovarian cancer is the leading cause of death among all gynecologic malignancies and the second most prevalent of the reproductive cancers (Siegel, Naishadham, & Jemal, 2012). According to the National Comprehensive Cancer Network ([NCCN], 2012b), the standard of care for advanced epithelial ovarian cancer (EOC) consists of an IV platinum and taxane-based chemotherapy for 6-8 cycles, or combination IV and intraperitoneal (IP) chemotherapy for patients with stage II or III cancer who have had optimally debulked (less than 1 cm residual) surgery (see Figure 1).

Members Only

Access to this article is restricted. Please login to view the full article.

Not a current ONS Member or journal subscriber?
Join/Renew Membership or